Literature DB >> 25083262

Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes.

Michael J Sorich1, Andrew Rowland2, Michael D Wiese3.   

Abstract

Year:  2014        PMID： 25083262      PMCID： PMC4110874          DOI： 10.1177/2042098613520030

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN： 2042-0986


× No keyword cloud information.
  36 in total

Review 1.  The role of cost-effectiveness analysis in the era of pharmacogenomics.

Authors:  Christopher R Flowers; David Veenstra
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 2.  The microeconomics of personalized medicine: today's challenge and tomorrow's promise.

Authors:  Jerel C Davis; Laura Furstenthal; Amar A Desai; Troy Norris; Saumya Sutaria; Edd Fleming; Philip Ma
Journal:  Nat Rev Drug Discov       Date:  2009-03-20       Impact factor: 84.694

3.  Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study.

Authors:  Anke-Hilse Maitland-van der Zee; Eric Boerwinkle; Donna K Arnett; Barry R Davis; Catherine Leiendecker-Foster; Michael B Miller; Olaf H Klungel; Charles E Ford; John H Eckfeldt
Journal:  Am Heart J       Date:  2007-01       Impact factor: 4.749

4.  Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses.

Authors:  Xin Sun; Matthias Briel; Stephen D Walter; Gordon H Guyatt
Journal:  BMJ       Date:  2010-03-30

5.  Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-analysis.

Authors:  Lawson Eng; Abul Kalam Azad; Steven Habbous; Vincent Pang; Wei Xu; Anke H Maitland-van der Zee; Sevtap Savas; Helen J Mackay; Eitan Amir; Geoffrey Liu
Journal:  Clin Cancer Res       Date:  2012-06-25       Impact factor: 12.531

Review 6.  Biomarker studies: a call for a comprehensive biomarker study registry.

Authors:  Fabrice Andre; Lisa M McShane; Stefan Michiels; David F Ransohoff; Douglas G Altman; Jorge S Reis-Filho; Daniel F Hayes; Lajos Pusztai
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

7.  The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.

Authors:  Deepak L Bhatt; Guillaume Paré; John W Eikelboom; Katy L Simonsen; Eileen S Emison; Keith A A Fox; Ph Gabriel Steg; Gilles Montalescot; Nihar Bhakta; Werner Hacke; Marcus D Flather; Koon-Hou Mak; Patrice Cacoub; Mark A Creager; Peter B Berger; Steven R Steinhubl; Gurunathan Murugesan; Shamir R Mehta; Kandice Kottke-Marchant; A Michael Lincoff; Eric J Topol
Journal:  Eur Heart J       Date:  2012-03-26       Impact factor: 29.983

8.  Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study.

Authors:  Michael M Hoffmann; Winfried März; Bernd Genser; Christiane Drechsler; Christoph Wanner
Journal:  Atherosclerosis       Date:  2011-08-05       Impact factor: 5.162

9.  Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group.

Authors:  Scott D Patterson; Nadine Cohen; Maha Karnoub; Sharada Louis Truter; Eileen Emison; Shirin Khambata-Ford; Brian Spear; Ekopimo Ibia; Rizwana Sproule; Diane Barnes; Anahita Bhathena; Michael R Bristow; Chris Russell; Dai Wang; Amelia Warner; Agnes Westelinck; William Brian; Amir Snapir; Monique A Franc; Peggy Wong; Peter M Shaw
Journal:  Pharmacogenomics       Date:  2011-07       Impact factor: 2.533

10.  The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.

Authors:  Steven M Teutsch; Linda A Bradley; Glenn E Palomaki; James E Haddow; Margaret Piper; Ned Calonge; W David Dotson; Michael P Douglas; Alfred O Berg
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822
View more
  5 in total

Review 1.  The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?

Authors:  Mafalda M Dias; Michael J Sorich; Andrew Rowland; Michael D Wiese; Ross A McKinnon
Journal:  Pharm Res       Date:  2017-02-24       Impact factor: 4.200

2.  Professional opportunity for pharmacists to integrate pharmacogenomics in medication therapy.

Authors:  Iris Cohn; Ronald D Cohn; Shinya Ito
Journal:  Can Pharm J (Ott)       Date:  2018-04-02

3.  Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?

Authors:  Rachel Huddart; Katrin Sangkuhl; Michelle Whirl-Carrillo; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2019-04-12       Impact factor: 6.875

Review 4.  Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future.

Authors:  Naomi J Rankin; David Preiss; Paul Welsh; Naveed Sattar
Journal:  Int J Epidemiol       Date:  2016-10-27       Impact factor: 7.196

Review 5.  Economic evaluations of personalized medicine: existing challenges and current developments.

Authors:  Fatiha H Shabaruddin; Nigel D Fleeman; Katherine Payne
Journal:  Pharmgenomics Pers Med       Date:  2015-06-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.